The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
Siemens Healthineers aims to grow its PET imaging business by picking up the radiodiagnostic manufacturing and distribution network of Novartis’ Advanced Accelerator Applications division. First reported by the Financial Times, the transaction will weigh in above 200 million euros and will include the production base behind radioactive tracers used in scans.
Galapagos is coming under additional pressure from investors. Having built a 9.9% stake in Galapagos, EcoR1 Capital is now planning to talk to the Belgian biotech about its performance and the composition of its board. EcoR1 has been building a position in Galapagos for several years. By June 2023, the biotech-focused investment fund had accumulated a 9.87% stake in the company.
